Clinical Management in Asthmatic Patients Attended in the Influential Area of Hospital Universitario Virgen de la Victoria, Málaga

Asthma Clinical Trial

— FIM-ASP-20201  

Official title:

Non-Interventional, Descriptive, Cross-sectional and Unicentric Study to Describe the Clinical Management in Asthmatic Patients Attended in the Influential Area of Hospital Universitario Virgen de la Victoria, Málaga

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04653116
• Other study ID #: FIM-ASP-2020-01
• Status: Recruiting
• Start date: November 1, 2020
• Est. completion date: June 30, 2021

Study information

• Verified date: November 2020
• Source: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This evidence raises the need to determine the assistance quality care in asthma population in the influential area of Hospital Universitario Virgen de la Victoria through the assistance quality care indicators established by GEMA guidelines. The aim of this study is to obtain clinical data that allow to assess assistance quality degree in order to find improvement opportunities to achieve a better control of asthmatic patients within this influential area.

Description:

Asthma is a heterogenic chronic disease characterized by acute symptomatic episodes of varying severity, including intermittently inflammation and narrowing of the airways in the lungs. The prevalence of this disease is high as affects more than 300 million people worldwide, which varies by country. In Spain, the prevalence it is estimated to be around 5%, ranged between 1% in Huelva and 4,7% in Albacete, according with the European Community Respiratory Survey (ECRHS), and seems to be increased due to a higher rate of asthma diagnosis1.

It's important to note that in this condition there is a substantial proportion of patients with inadequate control of their disease, which conducts to a higher morbidity and mortality2. The poor disease control is associated to an important negative impact in patient's health-related quality of life (HRQoL), causing them daily activity impairment, loss of work productivity and the need of using unscheduled doctor visits and hospital services3, 4. The direct and indirect costs in patients with a poor disease control represents an important proportion of the total cost of asthma, which it's estimated to be around 1-2% of the total public healthcare resources in developed countries, especially in patients with severe-persistent asthma4, 5.

The facts previously exposed turns this disease into a major public health problem due to its high prevalence within all age and sex groups and the high proportion of uncontrolled patients, which causes a high health burden to the National Health System, and which affects directly on the affected patients, as well as their families and the society6.

For this reason, during the past decades multiple clinical practice guidelines have been designed to improve the quality of care in patients with asthma and to reduce the high public burden associated to this disease7. International guidelines such as the Global Initiative for Asthma (GINA) and national guidelines as Guía Española para el Manejo del Asma (GEMA) in Spain, both of them stating that a good disease control can be achieved by most of asthma patients, were launched to increase the technical training of health professionals in order to reach a better disease management and conduct to a better quality of life in these patients 8, 9.

Specifically, GEMA guidelines also includes a tool to assess the level of assistance quality care through 8 indicators covering 4 dimensions: diagnose, non-pharmacological treatment, pharmacological treatment, monitoring.

However, since guidelines have been launched, there's still evidence of high proportion of patients with poorly disease control and large impact in patient's health-related quality of life10. Despite the availability of therapeutic recommendations through guidelines, clinical studies have shown that there's poor adherence to guidelines goals3. The Asthma Insight and Reality surveys, which were performed in several regions worldwide, concluded that all participating countries didn't met GINA goals. Specifically, in Central and Eastern Europe, the results showed a high proportion of asthma population who described physical activity limitations (68,2%) and acute symptoms during the previous 4 weeks (74%). Regarding disease monitoring, it' important to note that the results demonstrated that a 36,2% of asthmatic patients had never performed a lung function test11. A recent study conducted in Spain and Italy also evidenced a generally poor disease control, with around 50% of participant patients being considered uncontrolled12, and that strategies were needed to improve the management of this disease as it was concluded in a study performed in Spain to assess the disease control according to GINA criteria13.

In terms of costs, it's estimated that around 70% of the total cost of the disease is determined by this poor control and management14. An adequately disease management based in a higher use of preventive anti-inflammatory medication, a better education in asthma patients and an accurately follow of the recommendations of guidelines would result in a greater disease control and in a reduction of associated costs15, 16, 17.

This evidence raises the need to determine the assistance quality care in asthma population in the influential area of Hospital Universitario Virgen de la Victoria through the assistance quality care indicators established by GEMA guidelines. The aim of this study is to obtain clinical data that allow to assess assistance quality degree in order to find improvement opportunities to achieve a better control of asthmatic patients within this influential area.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: June 30, 2021
• Est. primary completion date: November 29, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patient with written informed consent prior to participation.

2. Patient female or male = 18 years of age

3. Patient with asthma diagnosis more than one year before the study inclusion

4. Clinical data available at least 1 year before the study inclusion in the electronic medical records.

Exclusion Criteria:

1. Patient's participation in any clinical trial during the year prior to the index date for data collection.

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
Spain	H. university virgen de la victoria	Málaga	Malaga

Sponsors (1)

Lead Sponsor	Collaborator
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To describe the clinical management in asthmatic	To describe the clinical management in asthmatic patients in the influential area of Hospital Universitario Virgen de la Victoria according to the assistant quality indicators established by GEMA guidelines	6 month
Secondary	To describe the sociodemographic and clinical characteristics	Age. Weight. Treatment. Exacerbations	6 month